GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Net Interest Income (for Banks)

Arovella Therapeutics (ASX:ALA) Net Interest Income (for Banks)


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Arovella Therapeutics Business Description

Traded in Other Exchanges
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.